Abstract
The clinical efficacy of ciprofloxacin was evaluated with 21 patients with soft tissue infection due mainly to gram-negative aerobic bacteria. Clinical cure was noted in 16 patients (76%), and clinical improvement was noted in the remaining 5 patients (24%). In addition, levels of ciprofloxacin were measured in the sera and tissues of 11 patients. Mean concentrations in tissue averaged 1.75 times the levels in serum. Ciprofloxacin should provide serum and soft tissue concentrations above the MICs for most gram-negative aerobic bacteria.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boerema J. B., Dalhoff A., Debruyne F. M. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy. 1985;31(1):13–18. doi: 10.1159/000238308. [DOI] [PubMed] [Google Scholar]
- Boerema J., Boll B., Muytjens H., Branolte J. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother. 1985 Aug;16(2):211–217. doi: 10.1093/jac/16.2.211. [DOI] [PubMed] [Google Scholar]
- Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dalhoff A., Eickenberg H. U. Tissue distribution of ciprofloxacin following oral and intravenous administration. Infection. 1985 Mar-Apr;13(2):78–81. doi: 10.1007/BF01660419. [DOI] [PubMed] [Google Scholar]
- Eron L. J., Harvey L., Hixon D. L., Poretz D. M. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother. 1985 Aug;28(2):308–310. doi: 10.1128/aac.28.2.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gonzalez M. A., Uribe F., Moisen S. D., Fuster A. P., Selen A., Welling P. G., Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):741–744. doi: 10.1128/aac.26.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ramirez C. A., Bran J. L., Mejia C. R., Garcia J. F. Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother. 1985 Jul;28(1):128–132. doi: 10.1128/aac.28.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Scully B. E., Neu H. C., Parry M. F., Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet. 1986 Apr 12;1(8485):819–822. doi: 10.1016/s0140-6736(86)90937-2. [DOI] [PubMed] [Google Scholar]